DCC: Sub-committee to look into one-time NOC for exports

The DCC has proposed including this concern in the sub-committee's investigation to explore potential relaxation of the destruction clause

249
DCC
DCC

Last Updated on September 30, 2024 by The Health Master

DCC

The Indian pharmaceutical industry is a global powerhouse, but navigating export regulations can be a hurdle. The Drugs Consultative Committee (DCC) is taking steps to simplify the process, particularly for unapproved, new drugs intended solely for export.

One-Time NOC and Manufacturing License: Examining the Possibilities

  • Industry Request: Pharmaceutical companies have requested a one-time export NOC (No Objection Certificate) and manufacturing license, followed by a Certificate of Pharmaceutical Product (CoPP), for unapproved, banned, or new drugs destined for export markets.
  • DCC’s Consideration: The DCC acknowledges potential benefits for approved and new drugs but expressed reservations about banned drugs due to misuse concerns.
  • Sub-Committee Formation: To thoroughly assess the pros and cons, the DCC has recommended forming a sub-committee dedicated to this issue.

Destruction of Unapproved Drugs: Addressing Economic Loss

  • Current Regulations: As per DCGI (Drugs Controller General of India) guidelines, any unapproved drugs manufactured for export but not shipped must be destroyed.
  • Industry Concerns: This requirement is seen as an economic burden, leading to wasted resources and lost profits.
  • Sub-Committee’s Review: The DCC has proposed including this concern in the sub-committee’s investigation to explore potential relaxation of the destruction clause.

Timely Exports: Balancing Efficiency and Control

  • Industry’s Argument: The current system, requiring repeated applications for NOCs and licenses for each export order, is time-consuming and delays shipments.
  • Past Practices: Previously, NOCs were obtained centrally from CDSCO before acquiring state-level manufacturing licenses.
  • Streamlining Efforts: In 2018, the process was decentralized, delegating NOC and license approvals to state authorities for faster turnaround.

Finding the Right Balance: The Sub-Committee’s Role

The newly formed sub-committee will play a crucial role in:

  • Evaluating the feasibility of a one-time NOC and manufacturing license system for specific categories of drugs.
  • Assessing the potential risks and benefits associated with relaxing the destruction clause for unapproved drugs.
  • Proposing recommendations for optimizing the export approval process while maintaining regulatory control.

Conclusion

The DCC’s initiative demonstrates a commitment to fostering a more efficient export environment for the Indian pharmaceutical industry.

By carefully examining the industry’s requests and potential solutions, the sub-committee’s findings can pave the way for a more streamlined and competitive export landscape.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

DCC

DTAB

Technical Committee

Hathi Committee

Mashelkar Committee

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news